Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Cambrex Reports First Quarter 2015 Financial Results

      - Sales increased 18% (27% excluding currency) and EBITDA increased $9.6 million vs. prior year quarter -

      - Strong sales and EBITDA growth continue to be expected in 2015 -

      - Conference call at 8:30 a.m. ET on May 1, 2015 -


      News provided by

      Cambrex Corporation

      May 01, 2015, 07:00 ET

      Share this article

      Share this article


      EAST RUTHERFORD, N.J., May 1, 2015 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM) reports results for the first quarter ended March 31, 2015.

      Highlights

      • Sales increased 18% compared to the first quarter of 2014, and increased 27% excluding foreign currency impact, driven by Innovator products and Controlled Substances.
      • EBITDA increased to $18.0 million from $8.4 million in the first quarter of 2014.
      • GAAP Diluted EPS from continuing operations was $0.26 versus $0.04 in the first quarter last year and Adjusted Diluted EPS was $0.29 compared to $0.07 in the same quarter last year.
      • Net Cash improved $22.4 million to $7.9 million compared to Debt, net of cash, of $14.5 million at December 31, 2014.
      • The Company continues to expect full year 2015 sales, excluding currency impact, to increase between 16% and 20% compared to 2014. Adjusted EBITDA is also still expected to be between $101 and $107 million, a 23% to 30% increase over 2014. Adjusted Diluted EPS from continuing operations continues to be expected to be between $1.62 and $1.75 per share, a 22% to 32% increase over 2014 (see Financial Expectations section below).

      "The first quarter was a great start to the year and keeps us on track for significant growth in 2015," commented Steven M. Klosk, President and Chief Executive Officer of Cambrex. "We saw strong demand in certain larger products within our Innovator product category and our Controlled Substances category also performed well against the first quarter last year.  Although the timing of shipments resulted in flat revenues in the first quarter compared to the same quarter last year, orders remain strong in our Generics product category.  These trends, along with our visibility into the rest of the year, give us a high level of confidence for the remainder of 2015.

      "As we announced earlier this year, we have been and will continue to invest aggressively in our plants.  We recently broke ground on a significant capacity expansion at our Charles City, Iowa facility, and additional facility upgrades and capacity expansions are underway at our Swedish and Italian sites to meet anticipated demand for 2016 and beyond."

      Basis of Reporting
      The Company has provided a reconciliation of GAAP amounts to adjusted (i.e. Non-GAAP) amounts at the end of this press release.  Cambrex management believes that the adjusted amounts provide useful information to investors due to the magnitude and nature of certain expenses recorded in the GAAP amounts.

      First Quarter 2015 Operating Results – Continuing Operations
      Sales were $78.2 million, compared to $66.2 million in the same period last year, representing an 18% increase.  Foreign exchange unfavorably impacted reported sales growth by 9%.  The sales increase primarily reflects higher volumes, partially offset by slightly lower pricing.  Certain branded active pharmaceutical ingredients (APIs) and controlled substances drove most of the growth. 

      Gross margins increased to 37% from 25% compared to the same period last year.  This increase was primarily due to higher plant utilization and favorable product mix.

      Selling, general and administrative expenses were $13.8 million compared to $11.6 million in the same period last year.  The increase was mainly due to higher personnel costs, sales and marketing expenses, recruiting, and pension expense, partially offset by a favorable impact from foreign exchange.

      Operating profit increased to $12.7 million from $2.5 million in the same period last year.  The increase in operating profit was primarily the result of higher gross profit, partially offset by higher operating expenses.  EBITDA was $18.0 million compared to $8.4 million in the same period last year. 

      The provision for income taxes was $3.8 million and resulted in an effective tax rate of 31% compared to an effective tax rate of 28% in the same period last year.  The increase in the rate is primarily attributable to a benefit recorded during the first quarter of 2014 for a partial reversal of a valuation allowance.

      Income from continuing operations was $8.4 million or $0.26 per share compared to $1.2 million or $0.04 per share in the same period last year.  Adjusted income from continuing operations was $9.2 million or $0.29 per share, compared to $2.2 million or $0.07 per share, respectively, in the same period last year (see table at the end of this release).

      Capital expenditures and depreciation were $12.0 million and $5.1 million, respectively, compared to $4.1 million and $5.8 million, respectively, in the same period last year. 

      Financial Expectations – Continuing Operations
      The following table shows the Company's current expectations for its full year 2015 financial performance.

         

      Expectations

      Gross sales increase

       

      16% - 20%

      Adjusted EBITDA

       

      $101 - $107 million

      Adjusted income from continuing operations per share

       

      $1.62 - $1.75

      Reduction of debt, net of cash

       

      $5 - 10 million

      Capital expenditures

       

      $80 - $85 million

      Depreciation

       

      $22 - $24 million

      Effective tax rate

       

      33% - 36%

      Consistent with prior years, these financial expectations are for continuing operations and exclude the impact of any potential acquisitions, restructuring activities and outcomes of tax disputes.  Sales expectations exclude the impact of foreign currency.  Adjusted EBITDA and Adjusted income from continuing operations per share are computed on a basis consistent with the reconciliation of the first quarter 2015 results in the tables at the end of this release.  The tax rate and amount of cash taxes paid will be sensitive to the geographic mix of income. 

      The financial information contained in this press release is unaudited, subject to revision and should not be considered final until the Company's first quarter 2015 Form 10-Q is filed with the SEC.

      Conference Call and Webcast
      A conference call to discuss the Company's first quarter 2015 results will begin at 8:30 a.m. Eastern Time on Friday, May 1, 2015 and can be accessed by calling 1-888-468-2440 for domestic and +1-719-325-2454 for international.  Please use the passcode 7993632 and call approximately 10 minutes prior to the start time.  A webcast will be available in the Investors section on the Cambrex website located at www.cambrex.com.  A telephone replay of the conference call will be available through Friday, May 8, 2015 by calling 1-888-203-1112 for domestic and +1-719-457-0820 for international.  Please use the passcode 7993632 to access the replay. 

      About Cambrex
      Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  The Company offers Active Pharmaceutical Ingredients ("APIs"), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products.  For more information, please visit http://www.cambrex.com/www.cambrex.com.  

      Forward Looking Statements
      This document contains "forward-looking statements," including statements or tables regarding expected performance, especially those set forth under the heading "Financial Expectations – Continuing Operations," "Highlights" and those attributed to our President and Chief Executive Officer in this document.  These and other forward looking statements may be identified by the fact that they use words such as "guidance," "expects," "anticipates," "intends," "estimates," "believes" or similar expressions.  Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations.  The factors described in Item 1A of Part I of the Company's Annual Report on Form 10-K for the period ended December 31, 2014, captioned "Risk Factors," or otherwise described in the Company's filings with the SEC provide examples of such risks and uncertainties that may cause the Company's actual results to differ materially from the expectations the Company describes in its forward-looking statements, including, but not limited to, pharmaceutical outsourcing trends, competitive pricing or product developments, market acceptance and adoption rate of our customers' products, government legislation and regulations (including those pertaining to environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation, environmental matters, changes in foreign exchange rates, uncollectible receivables, the timing of orders or shipments and the Company's ability to meet its production plan and its customer delivery schedules, loss on disposition of assets, cancellations or delays in renewal of contracts, lack of suitable raw materials, the Company's ability to receive regulatory approvals for its products and continued demand in the U.S. for late stage clinical products or the successful outcome of the Company's investment in new products.

      For further details and a discussion of these and other risks and uncertainties, investors are encouraged to review the Cambrex Annual Report on Form 10-K for the fiscal year ended December 31, 2014, including the Forward-Looking Statement sections therein, and other filings with the SEC.  The Company cautions investors and potential investors not to place significant reliance on the forward-looking statements contained in this press release and to give careful consideration to the risks and uncertainties listed above and contained in our SEC filings. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements.

      Use of Non-GAAP Financial Measures
      EBITDA, Adjusted EBITDA and Adjusted Income from Continuing Operations are non-GAAP financial measures.  The Company defines EBITDA as operating profit plus depreciation and amortization expense and Adjusted Income from Continuing Operations and Adjusted EBITDA are calculated in a manner consistent with that shown in the tables at the end of this release.   Other companies may have different definitions of EBITDA, Adjusted EBITDA and Adjusted Income from Continuing Operations, therefore, these measures may not be comparable with non-GAAP financial measures provided by other companies.  EBITDA, Adjusted EBITDA and Adjusted Income from Continuing Operations should not be considered alternatives to measurements required by U.S. GAAP, such as net income or operating profit, and should not be considered a measure of Cambrex's liquidity.  Cambrex uses EBITDA, Adjusted EBITDA and Adjusted Income from Continuing Operations among several other metrics to assess and analyze its operational results and trends.  Cambrex also believes EBITDA, Adjusted EBITDA and Adjusted Income from Continuing Operations are useful to investors because they are common operating performance metrics as well as metrics routinely used to assess potential enterprise value.  Cambrex has provided a reconciliation of U.S. GAAP amounts to non-GAAP amounts at the end of this press release.

      CAMBREX CORPORATION

      Statements of Profit and Loss

      For the Quarters Ended March 31, 2015 and 2014

      (in thousands, except per-share data)

                         
         

      2015

         

      2014

             

      % of

             

      % of

         

      Amount

       

      Sales

         

      Amount

       

      Sales

                         

      Gross Sales

      $

      78,184

           

      $

      66,192

         

           Commissions, Allowances and Rebates

       

      451

             

      549

         

      Net Sales

       

      77,733

             

      65,643

         
                         

           Other

       

      (208)

             

      462

         
                         

      Net Revenues

       

      77,525

             

      66,105

         
                         

           Cost of Goods Sold

       

      48,446

       

      62.0%

         

      49,527

       

      74.8%

                         

      Gross Profit

       

      29,079

       

      37.2%

         

      16,578

       

      25.0%

                         

      Operating Expenses

                       

           Selling, General and Administrative Expenses

       

      13,751

       

      17.6%

         

      11,633

       

      17.6%

           Research and Development Expenses

       

      2,655

       

      3.4%

         

      2,475

       

      3.7%

      Total Operating Expenses

       

      16,406

       

      21.0%

         

      14,108

       

      21.3%

                         

      Operating Profit

       

      12,673

       

      16.2%

         

      2,470

       

      3.7%

                         

      Other Expenses:

                       

           Interest Expense, Net

       

      476

             

      522

         

           Other Expenses, Net

       

      62

             

      328

         
                         

      Income Before Income Taxes

       

      12,135

       

      15.5%

         

      1,620

       

      2.4%

                         

           Provision for Income Taxes

       

      3,767

             

      454

         
                         

      Income from Continuing Operations

      $

      8,368

       

      10.7%

       

      $

      1,166

       

      1.8%

                         

      Loss from Discontinued Operations, Net of Tax

       

      (375)

             

      (184)

         
                         

      Net Income

      $

      7,993

       

      10.2%

       

      $

      982

       

      1.5%

                         

      Basic Earnings/(Loss) per Share of Common Stock:

                       

         Income from Continuing Operations

      $

      0.27

           

      $

      0.04

         

         Loss from Discontinued Operations, Net of Tax

      $

      (0.01)

           

      $

      (0.01)

         

         Net Income

      $

      0.26

           

      $

      0.03

         
                         

      Diluted Earnings/(Loss) per Share of Common Stock:

                       

         Income from Continuing Operations

      $

      0.26

           

      $

      0.04

         

         Loss from Discontinued Operations, Net of Tax

      $

      (0.01)

           

      $

      (0.01)

         

         Net Income

      $

      0.25

           

      $

      0.03

         
                         

      Weighted Average Shares Outstanding

                       

           Basic

       

      31,198

             

      30,546

         

           Diluted

       

      32,158

             

      31,408

         
                         
                         

      CAMBREX CORPORATION

      Consolidated Balance Sheets

      As of March 31, 2015 and December 31, 2014

      (in thousands)

                 
                 
         

      March 31,

         

      December 31,

      Assets

       

      2015

         

      2014

                 

      Cash and Cash Equivalents

      $

      67,910

       

      $

      45,518

      Trade Receivables, Net

       

      41,475

         

      77,124

      Other Receivables

       

      6,744

         

      10,610

      Inventories, Net

       

      107,721

         

      85,630

      Prepaid Expenses and Other Current Assets

       

      9,319

         

      8,688

        Total Current Assets

       

      233,169

         

      227,570

                 

      Property, Plant and Equipment, Net

       

      158,994

         

      163,567

      Goodwill

       

      40,863

         

      43,912

      Intangible Assets, Net

       

      9,301

         

      8,902

      Deferred Income Taxes

       

      35,318

         

      38,424

      Other Non-Current Assets

       

      3,438

         

      4,697

                 

        Total Assets

      $

      481,083

       

      $

      487,072

                 

      Liabilities and Stockholders' Equity

               
                 

      Accounts Payable

      $

      43,435

       

      $

      43,670

      Deferred Revenue

       

      29,684

         

      14,095

      Accrued Expenses and Other Current Liabilities

       

      33,049

         

      41,014

        Total Current Liabilities

       

      106,168

         

      98,779

                 

      Long-Term Debt

       

      60,000

         

      60,000

      Deferred Income Taxes

       

      8,863

         

      10,545

      Accrued Pension Benefits

       

      47,330

         

      50,949

      Other Non-Current Liabilities

       

      14,523

         

      15,573

                 

        Total Liabilities

      $

      236,884

       

      $

      235,846

                 

        Stockholders' Equity

      $

      244,199

       

      $

      251,226

                 

        Total Liabilities and Stockholders' Equity

      $

      481,083

       

      $

      487,072

                 

      CAMBREX CORPORATION

      Reconciliation of GAAP to non-GAAP Results

      For the Quarters Ended March 31, 2015 and 2014

      (in thousands)

                   
       

      First Quarter 2015

         

      First Quarter 2014

                   

      Operating Profit

      $

      12,673

         

      $

      2,470

                   

      Depreciation and Amortization

       

      5,297

           

      5,883

                   

      EBITDA

      $

      17,970

         

      $

      8,353

                   

      CAMBREX CORPORATION

       

      Reconciliation of GAAP to non-GAAP Results

       

      For the Quarters Ended March 31, 2015 and 2014

       

      (in thousands)

       
                                   
             

      First Quarter 2015

       

      First Quarter 2014

         
                   

      Diluted EPS

             

      Diluted EPS

         

      Income from Continuing Operations

      $

      8,368

      $

      0.26

       

      $

      1,166

      $

      0.04

         
                                   

      Stock-Based Compensation, Net of Tax1

       

      700

       

      0.02

         

      720

       

      0.02

         

      Amortization of Purchased Intangibles

       

      169

       

      0.01

         

      274

       

      0.01

         
                                   

      Adjusted Income from Continuing Operations

      $

      9,237

      $

      0.29

       

      $

      2,160

      $

      0.07

         
                                   
                                   
                                   
                                   

      1   Tax rate estimated at 35% for stock-based compensation.

      SOURCE Cambrex Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.